Alterations in metabolism-related genes, such as IDH1 mutation, O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation, or epidermal growth factor receptor (EGFR) amplification, are frequent in glioma patients and are closely related to prognosis (12–15). The gene discussed is EGFR; the disease is central nervous system cancer.